R-3750 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 97 | Ulcerative colitis | 1 |
97. Ulcerative colitis
Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05666960 (ClinicalTrials.gov) | February 27, 2023 | 1/12/2022 | R-3750 in Patients With Mild to Moderate Ulcerative Colitis | A Single and Repeat Dosing Study of the Safety, Drug Exposure, and Clinical Activity of R-3750 in Patients With Mild to Moderate Ulcerative Colitis | Ulcerative Colitis Chronic Mild;Ulcerative Colitis Chronic Moderate;Ulcerative Colitis Chronic;Ulcerative Colitis | Drug: R-3750 | Rise Therapeutics LLC | Mayo Clinic;University of Colorado, Denver | Recruiting | 18 Years | 65 Years | All | 36 | Phase 1 | United States |